Stockscreener 앱 받기
1.41
16.57%
-0.28
전일 마감가:
$1.69
열려 있는:
$1.69
하루 거래량:
63,193
Relative Volume:
0.28
시가총액:
$2.73M
수익:
-
순이익/손실:
$-9.32M
주가수익비율:
-0.1109
EPS:
-12.7107
순현금흐름:
$-7.30M
1주 성능:
-25.40%
1개월 성능:
-31.88%
6개월 성능:
-50.70%
1년 성능:
-74.73%
1일 변동 폭
$1.40
$1.70
1주일 범위
$1.40
$1.93
52주 변동 폭
$1.40
$7.461
Tharimmune Inc Stock (THAR) Company Profile
명칭
Tharimmune Inc
전화
302-743-2995
주소
1200 ROUTE 22 EAST, BRIDGEWATER
THAR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.41 | 2.73M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Tharimmune Inc 주식(THAR)의 최신 뉴스
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald
Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - ACCESS Newswire
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - ACCESS Newswire
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - ACCESS Newswire
tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India
tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada
Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN
Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com
Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com
Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune
Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN
Tharimmune announces $2.02M private placement; shares up - MSN
Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World
Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN
Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria
THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan
Tharimmune secures $2.02 million in private funding - Investing.com
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Eagle-Tribune
Tharimmune Secures $2M Strategic Investment to Advance Chronic Pruritus Treatment Pipeline - StockTitan
Rodman & Renshaw sets price target on Tharimmune shares, rating Buy - Investing.com
Tumor necrosis factor (TNF)-alpha Inhibitor Market Will Witness Growth with Emerging Therapies by 2034 | - EIN News
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 - AccessWire
Tharimmune appoints new board member, cancels Intract merger By Investing.com - Investing.com South Africa
Tharimmune appoints new board member, cancels Intract merger - Investing.com
Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch
Penn State wins trademark case over retailer's use of vintage logos, images - Corsicana Daily Sun
Oil company Phillips 66 faces federal charges related to alleged Clean Water Act violations - Corsicana Daily Sun
Valsoft Corporation Enters the Book Industry Software Space with the Acquisition of Edelweiss - Corsicana Daily Sun
Travelers Capital and TCC Financial Bolster Investor Relations Service, Compliance, and Growth with the Appointment of Mark Breakspear - Corsicana Daily Sun
Oleria Named a Winner in Fast Company's 2024 Next Big Things in Tech Awards - Corsicana Daily Sun
Congratulations to Tenorshare for Winning French Design Award - Corsicana Daily Sun
LQR House Inc. Board of Directors Approves Purchase of Up to $1M Bitcoin as Treasury Reserve Asset and Retention of Up to $10M Crypto Payments on CWSpirits.com - Corsicana Daily Sun
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Corsicana Daily Sun
Sterling Metals Completes 3D IP Survey at Copper Road, Discovers New Outcrop Areas and Extends Mineralized Footprint - Corsicana Daily Sun
BofA Strengthens Support for Arizona Entrepreneurs through State’s Largest Supplier Diversity Program Impact AZ - Corsicana Daily Sun
Diversified Announces Upcoming Investor Engagement - Corsicana Daily Sun
What's Going On With Tharimmune Shares Monday? - Benzinga
MSP Recovery announces 1-for-25 reverse stock split to regain Nasdaq compliance - MSN
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada
Tharimmune Inc (THAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
0.33%
자본화:
|
볼륨(24시간):